Dr. Mayo is the Parker Chair in Psychedelics Research at the University of Calgary; Will advise PharmAla on clinical trial design and execution
VANCOUVER, BC, October 13, 2022 /CNW/ PharmAla Biotech (CSE:MDMA) is excited to welcome Dr. Leah Mayo to the company’s Scientific Advisory Board. Dr. Mayo recently took up the role of Parker Chair in Psychedelics Research at the Department of Psychiatry, the Hotchkiss Brain Institute, and the Mathison Centre for Mental Health Research and Education at the University of Calgary. Prior to her appointment, Dr. Mayo was Assistant Professor at the Center for Social and Affective Neuroscience, Linköping University (Sweden).
Joining Dr. Harriet de Wit, Dr. Malik Slassi and Dr. Leonard Howell on PharmAla’s scientific advisory board, Dr. Mayo’s primary responsibility will be advising the Company on the design of clinical trials which it will present to the USFDA and other global health regulatory bodies.
“I’m excited about the contribution that Dr. Mayo will make to our team. She’s a young, exciting researcher – who has already achieved a remarkable pedigree,” said Nicholas Kadysh, CEO of PharmAla Biotech. “In the near future, as we move ALA-002 to an IND filing with the US FDA, and a similar filing in other countries, I know that Leah’s help will be invaluable.”
PharmAla’s primary research into its ALA and ABA series of molecules has established compelling evidence that both series of Novel Chemical Entities (NCEs) represent an improved safety profile from traditional, generic MDMA, while retaining efficacy. PharmAla intends to bring the ALA series to clinical trial in 2022.
"The potential of an MDMA-like compound with an improved safety profile is really exciting,“ said Dr. Leah Mayo. “I’m grateful for the opportunity to help guide PharmAla’s clinical trial program as they continue their efforts to advance the field of psychedelic medicine.”
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca